Background--Arginase II activity contributes to reciprocal regulation of endothelial nitric oxide synthase (eNOS). We tested the hypotheses that arginase II activity participates in the regulation of Ca 2+ /Ca 2+ /calmodulin-dependent kinase II/eNOS activation, and this process is dependent on mitochondrial p32.
N itric oxide (NO) plays a key role in the maintenance of vascular homeostasis by modulating vascular tone, as well as vascular smooth muscle cell proliferation and migration. Endothelial dysfunction defined as decreased NO production is considered an initial and critical event in vascular diseases such as atherogenesis, causing vascular stiffness. 1 In reciprocal regulation of NO synthase (NOS) by arginase, upregulation of arginase activity contributes to vasoregulatory dysfunction. 2 Two isoforms of arginase, arginase I, and arginase II encoded by different genes, 3 exhibited distinct expression patterns. 4 Arginase I is considered the hepatic isoform catalyzing the final step in the urea cycle, and its expression can be induced by hypoxia and lipopolysaccharide. 5 Arginase II, as the extrahepatic isoform, is the principal form in human and mouse aortic endothelial cells (ECs) and provides L-ornithine for the synthesis of polyamines, putrescine, spermidine, and spermine (SPM), associated with cell proliferation and differentiation. 6, 7 Arginase II is also inducible by hypoxia, lipopolysaccharide, and tumor necrosis factor-a, [8] [9] [10] and increased arginase II activity in ECs has recently been extended to other disorders in animal models, including aging, 11 ischemic reperfusion, 12, 13 hypertension, 14, 15 balloon injury, 16 and atherosclerosis. 2 Although arginase II participates in the endothelial dysfunction, the mechanism through which endothelial NOS activity is regulated remains unclear. However, a novel mechanism showed that oxidized lowdensity lipoprotein triggered translocation of arginase II from mitochondria to the cytoplasm via mitochondrial processing peptidase with a simultaneous increase in arginase activity that drove endothelial nitric oxide synthase (eNOS) uncoupling by depleting the substrate pool available for NO biosynthesis. 17 Similarily, we also showed that an arginase inhibitor-enhanced eNOS phosphorylation at Ser1177 18 and arginase II inhibition improved the loss of mitochondrial membrane potential by a Ca 2+ -dependent mechanism and prevented mitochondrial reactive oxygen species (ROS) production. 19 eNOS activity can be regulated by various extracellular signals, including subcellular targeting, and protein-protein interactions. In these regulations, Ca 2+ principally contributes to modulation of eNOS activity. p32, also known as HABP1 (hyaluronan-binding protein 1), is a receptor for gC1qR (globular head domains complement 1q), or C1qbp (complement 1q-binding protein), and has been recognized as a pre-mRNA splicing factor SF2-binding protein in the nucleus 23 and a receptor interacting with the complement component C1q on the cell surface. 24 Although p32 can be existed in multicellular compartments, it is predominantly targeted to mitochondria because of the mitochondrial targeting sequence contained in the 73N-terminal amino acids. 25 Functional studies have shown that p32 is required for the induction of mitochondria-dependent cell death 26, 27 and for the metabolic shift between oxidative phosphorylation and aerobic glycolysis. 28 Moreover, the crystal structure of p32 has been determined and indicates that p32 can form a pore-like homotrimer and may serve as a high-capacity divalent cation storage protein. 29 However, in ECs, the function of p32 and its regulatory mechanism remain unknown. Therefore, we investigated whether arginase II activity participates in the regulation of cytosolic Ca 2+ concentration ([Ca 2+ ]c) and mitochondrial Ca 2+ concentration ([Ca 2+ ]m) that may be associated with Ca 2+ -dependent eNOS activation. We also examined the function of p32 as a Ca 2+ -modulating protein in mitochondria and investigated the regulatory mechanism between arginase II and p32. Finally, we tested whether the small interfering RNA (siRNA) against p32 (sip32) restored endothelial dysfunction in the atherogenic mouse model (ApoE
-null) fed a high-cholesterol diet (HCD).
Materials and Methods
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Clinical Perspective
What Is New?
• • Arginase II participates in endothelial dysfunction by contributing to the regulation of intracellular Ca 2+ concentration in an NO-independent manner.
What Are the Clinical Implications?
• p32, an a cytosol/mitochondria Ca 2+ regulator, was identified as a new therapeutic target for vascular disorders in which NO production was interrupted and injurious reactive oxygen species generation was promoted.
Materials
The 2(S)-amino- Chungbuk, Korea, n=15) were obtained at 10 weeks of age and fed a normal diet (ND) or a high-cholesterol diet (HCD, D12108C, Research Diet Inc.) for 8 weeks, respectively. ApoE À/À mice fed an HCD were administered with scramble (scm) or siRNA against p32 (sip32) by intravenous injection (30 lmol/L/mouse per day, dissolved in PBS, with an injection volume of 50 lL) 5 times with 2-day intervals before experiments were performed. Two pairs of the arginase II knockout (KO) breeders with a C57BL/6 background were a generous gift from Professor Jaye P.F. Chin-Dusting for establishment of a colony at Kangwon National University Animal Services Facility and 10-week male mice (n=15) were used for all experiments. The study was approved in accordance with the Guide for the Care and Use of Laboratory Animals (approval no. KW-17002, Institutional Animal Care and Use Committee, Kangwon National University) and adhered to guidelines that are in compliance with the current international laws and policies (Guide for the Care and Use of Laboratory Animals, The National Academies Press, 8th edition, 2011).
Isolation of Mouse Endothelial Cells
Endothelial cells were isolated from the aorta of anesthetized mice of WT, Arg II À/À , and ApoE À/À mice as previously described. 2 All experiments were performed with the second passage of endothelial cells.
siRNA Treatment and Knockdown of Mitochondrial p32
For siRNA transfection, HUVECs were incubated in starvation medium (DMEM plus 5% FBS and antibiotics) containing siRNA against p32 (sip32, 100 nmol/L, 5 0 -TGT CTC CGT CGG TGT GCA GC-Cy5-3 0 ), scramble siRNA (scmRNA) (100 nmol/L, 5 0 -GCT GCA CAC CGA CGG AGA CA-Cy5-3 0 ) or no oligonucleotide for 24 hours without a reagent. Dissected thoracic aortas of mice were incubated for 24 hours in DMEM (2% FBS, 100 U/mL penicillin and 100 lg/mL streptomycin) containing sip32 (100 nmol/L, 5 0 -TGT CTC CTT CCG TGT GCA GA-Cy5-3 0 ) and scmRNA (100 nmol/L, 5 0 -CAG CAC AGC CCT GGA GCA CCCy5-3 0 ).
Arginase Activity Assay
Arginase activity was assessed by measuring urea content using a-isonitrosopropiophenone as previously described. 2 Briefly, supernatants of extracted cell lysates were prepared by incubation with lysis buffer (Tris-HCl 50 mmol/L, pH 7.5, EDTA 0.1 mmol/L, and protease inhibitors) for 30 minutes at 4°C and centrifugation for 20 minutes at 14 000 g at 4°C.
Aortic vessel samples were assayed following homogenization in lysis buffer. 
Measurement of NO and ROS

Aortic Vascular Tension Assay
Heparin was administered 1 hour before mice were euthanitized. Mice were anesthetized using isoflurane, and the thoracic aorta from aortic root to the bifurcation of the iliac arteries was rapidly isolated and cut into 1. 
Western Blot Analysis
Aortic vessels and cell lysates were subjected to SDS-PAGE followed by Western blot. 2 Band intensities were analyzed using NIH ImageJ.
Polyamine and L-Arginine Analyses
Intracellular concentrations of L-arginine (L-Arg) and polyamine, spermine (SPM), spermidine, and putrescine were determined using high performance liquid chromatography (HPLC) with pre-column derivatization with o-phthalaldehyde according to a modification of previously published methods. 30 Briefly, L-arginine (100 lmol/L) and polyamine 
Mitochondrial Fractionation
Cells and aortic segments were homogenized twice in subcellular fractionation buffer (sucrose 250 mmol/L, HEPES 20 mmol/L, pH 7.4, KCl 10 mmol/L, MgCl 2 1.5 mmol/L, EDTA 1 mmol/L, EGTA 1 mmol/L, and protease inhibitors (Roche Co.)) for 3 minutes and centrifuged at 1000 g for 10 minutes to remove cell debris and unbroken cells. The supernatants were centrifuged at 21 000 g for 45 minutes at 4°C. The cytosolic (supernatant) and mitochondrial (precipitate) fractions containing 20 lg proteins were used for subsequent Western blot analyses. Purity of the fractions was measured using Western blotting for HSP60 and actin, respectively.
MALDI-TOF Mass Spectrometry
p32 protein (200 ng in distilled water, pH7.4, Abcam Co.) and polyamine, L-Arg, and L-ornithine (10 mmol/L) were incubated for 1 hour at room temperature. MALDI-TOF mass spectrometry analyses were performed using a Bruker Autoflex speed TOF/TOF mass spectrometer (Billerica, MA). Analyses were performed in the reflector mode at a mass range of 20 000 to 45 000 m/z with an accelerating voltage of 20 kV and a delay time of 300 ns. The instrument was externally calibrated. A low-mass gate value of 20 000 m/z was selected to avoid saturation of the detector. 2,5-Dihydroxybenzoic acid at 10 mg/mL in 70% acetonitrile-0.1% trifluoroacetic acid was used as a matrix.
Fluorescence Immunoassay
Monoclonal antibody against p32 (Abcam Co. Cambridge, MA) was coated onto 96-well plates for 2 hours at 37°C with shaking at 150 rpm, and unbound antibody was removed by washing with phosphate-buffered saline with Tween 20 (PBST). Unbound sites in wells were blocked with bovine serum albumin (3% in PBST) for 1 hour at 37°C, followed by washing with PBST. The prepared p32 protein (500 ng/100 lL) was added to the wells and incubated for 2 hours at 37°C, and followed by washing with PBST. Next, different concentrations of Rhodamine B-tagged SPM were added to the wells and incubated for 1 hour at 37°C, and the wells were washed 5 times with PBST. The fluorescence intensity of each well was read at 553 nm excitation and 627 nm emission using epifluorescence microscopy (109 objective lens) equipped with the Metamorph program. K d values were calculated using GraphPad Prism 5 software.
Ion Chromatography p32 (10 ng and 100 ng) was added to Ca 2+ standard solutions (1 lg/mL, Merck Co., Darmstadt, Germany) and incubated for 30 minutes at 37°C. The solutions were filtered using the centrifugal filter Amicon Ultra-4 (ultracel-3K, Cork, Ireland) and the filtrates (25 lL) were subjected to ion column (cation analytical column, 49250 nm CS12A) chromatography (Thermo Dionex, ICS-5000+) equipped with a DC detector at a 1 mL/min flow rate.
Statistics
Each graph represents cumulative data from 3 independent experiments performed at least in triplicate. Statistical significance was determined using one-way ANOVA (mean AESEM) with a post hoc test or t test (meanAESEM) or twoway ANOVA (meanAESD; GraphPad Prism 5 software). A P<0.05 was considered statistically significant.
Results
Arginase chelator BAPTA-AM ( Figure 2C ). Furthermore, CaMKII inhibition with KN93 prevented siArgII-dependent eNOS Ser1177 phosphorylation (Figure 2D) 29 We designed siRNA against mitochondriatargeted p32 (sip32) and tested the efficacy according to incubation time and dose. As shown in Figure 3A (top and bottom), incubation of 100 nmol/L sip32 for 24 hours showed significant inhibition of p32 expression in both mitochondrial and cytosolic fractions. Under the same conditions, sip32 treatment decreased [Ca 2+ ]m ( Figure 3B) and increased [Ca 2+ ]c ( Figure 3C ). Furthermore, sip32 dosedependently increased the phosphorylation of CaMKII and eNOS Ser1177, however, the eNOS Thr495 phosphorylation was decreased ( Figure 3D ). sip32 incubation resulted in increased [Ca 2+ ]c ( Figure 3E ) based on fluorescence-activated cell sorting analysis, and pretreatment with the CaMKII inhibitor, KN-93 prevented sip32-dependent eNOS Ser1177 phosphorylation ( Figure 3F ). dose-dependently in p32 and was completely recovered with SPM preincubation ( Figure S2G ). These results suggest that the Ca 2+ -storage capacity of p32 may be regulated by SPM level. Finally, we analyzed the phosphorylation of CaMKII and eNOS caused by SPM stimulation in the siRNApreincubated HUVECs. SPM stimulation significantly reduced the phosphorylation of CaMKII and eNOS Ser1177, but increased eNOS Thr495 phosphorylation in both siRNA-untreated and -treated HUVECs ( Figure 4D ). Consistent with the results shown in Figure 3D , only sip32 incubation increased the phosphorylation of CaMKII and eNOS Ser1177 ( Figure 4D ). Next, whether arginase regulates the concentration of intracellular SPM and the expression of mitochondrial p32 was investigated. First, in intracellular SPM concentration analysis using HPLC, arginase inhibition and siArgII incubation significantly reduced SPM concentration ( Figure 5A ). siArgII-dependent downregulation of arginase II protein downregulated p32 at protein level ( Figure 5B ). p32 level was reduced in the aortas of arginase II KO mice, ( Figure 5C ), however, intracellular L-Arg and SPM concentrations did not differ from those of WT mice ( Figure 5D ). Conversely, increased arginase II protein level of in the aortas of eNOS KO mice and increased p32 level were observed ( Figure S3A and S3B Figure 6A ) and induced the phosphorylation of CaMKII and eNOS Ser1177, but blocked eNOS Thr495 phosphorylation ( Figure 6B ). NO production in endothelia was significantly enhanced ( Figure 6C ) and ROS production was prevented ( Figure 6D ) in sip32-treated vessels compared with ABH-treated aortic vessels from WT mice and aortic vessels from arginase II KO mice. Furthermore, sip32 augmented Ach-dependent vasorelaxation ( Figure 6E , ]m were increased in ApoE À/À mice fed an HCD and intravenous administration of sip32 improved endothelial dysfunction [p32]m in the aortas of age-matched WT and ApoE-null mice was analyzed. As shown in Figure S6A , [p32]m was not different between these mice, however, ox-LDL time-dependently induced p32 expression ( Figure S6B ). Therefore, based on the results, an HCD may play an important role in p32 expression. Since sip32 enhanced NO production in mouse aortas and increased expression of p32 in the aortas from ApoE-null mice fed an HCD, we investigated whether intravenous administration of sip32 restores endothelial dysfunction in ApoE-null mice fed an HCD. Administration of sip32 downregulated increased p32 expression ( Figure 7E ) and improved the phosphorylation of CaMKII and eNOS Ser1177, however, eNOS Thr495 phosphorylation was decreased ( Figure 7F ) in the aortas of ApoE-null mice fed an HCD. Furthermore, sip32 restored the attenuated NO production ( Figure 7G ) and augmented ROS generation ( Figure 7H ) in ApoE-null mice fed an HCD. In the vascular tension assay, sip32 significantly improved Ach-dependent vasorelaxation ( Figure 7I , log EC 50 ; WT versus ApoE À/À +HCD, Figure 7I ). As shown in Figure S7 , fluorescent-labeled siRNAs were predominantly localized in the endothelia of aortic vessels.
SPM Triggers Ca
Discussion
In the present study, we showed that arginase II inhibition decreased regulation between the cytosol and mitochondria. One mechanism involves arginase II activity that controls the concentration of free SPM, a key molecule inducing decreased eNOS-dependent NO release through augmented phosphorylation at Thr495 and attenuated phosphorylation at eNOS Ser1177 ( Figure 4D ). In the present study, SPM level was controlled by arginase activity in HUVECs with arginase downregulation, ABH, and siArgII, ( Figure 5A ) and in ApoE À/À mice fed an HCD with increased arginase activity ( Figure 7B and 7C). Reportedly, intracellular SPM mostly binds to RNA, DNA, and phospholipids, as well as ATP at submillimolar levels (<mmol/L) and free SPM at lmol/L levels. 31 In our experiments, the measured SPM concentration was 18AE3.4 lmol/ L in HUVECs and 8AE2.1 lmol/L in the aorta of WT mice. SPM, a biological polyamine, has various biological functions and can be taken up by mitochondria. 32 Among the polyamines, putrescine, spermidine, and SPM, only SPM with 4 amino groups induced an increase in p32-dependent [Ca 2+ ]m ( Figure 4C ). This difference in polyamine activity is likely attributable to the different polycationic structures of these compounds, which accounts for their flexibility and hydration. Because of the presence of 2 N atoms in the middle of the molecule, SPM is the most flexible of the 3 polyamines and has positive charges at fixed lengths along a conformationally flexible carbon chain, which can bridge critical distances. 33 As shown in MALDI-TOF analysis ( Figure S2B ), only SPM could bind to p32, at the ratio of 1:1. These SPM properties may affect the Ca 2+ -binding capacity of p32 ( Figure S2F and S2G). Fluorescence immunoassay ( Figure S8 ) showed that only rhodamine B-tagged SPM bound to p32, with a dissociation constant (K d ) of 66.2AE4.8 lmol/L. The high K d value may be attributed to rhodamine B tag conjugated to one of the SPM amino groups. We also found that urea, a product of arginase reaction, had no effect on the Ca 2+ -binding capacity of p32. The second mechanism is involved in the association of the arginase II protein level with p32 protein level observed in HUVECs treated with siArgII ( Figure 5B ) and in the aortas of ArgII À/À mice ( Figure 5C ), however, treatment of HUVECs with ABH and L-Arg had no effect on p32 protein level ( Figure S4A and S4B ). In the aortas of ArgII À/À mice, L-Arg and SPM concentrations were not changed ( Figure 5D ), however, decreased p32 expression, increased [Ca 2+ ]c, and increased eNOS Ser117 phosphorylation were observed. Furthermore, p32 protein level did not effect on arginase II protein level ( Figure S4C ) or arginase activity ( Figure S4D ). Therefore, these results suggested that arginase II protein may be involved in the regulation of p32 protein stability without affecting on protein synthesis because siArgII did not downregulated HSP60 protein level ( Figure 5B ) and siArgII did not also have an effect on mRNA level of p32 in quantitative real-time PCR (qRT-PCR) analysis. The regulation of p32 level apparently differs between humans and mice. In mice, increased arginase activity without a change of protein abundance 2 showed increased p32 level ( Figure 7A and 7B). However, in HUVECs, arginase II protein level, not activity, was associated with p32 level (Figure S4A and S4C) . Additionally, the half-life of p32 was %6 hours in cycloheximide-treated HUVECs. Therefore, arginase II plays an important role in mediating intracellular [Ca 2+ ] between mitochondria and cytosol through a p32-dependent mechanism. p32 has both mitochondrial and non-mitochondrial localization, although p32 predominantly targets to mitochondria with an N-terminal mitochondria-targeting sequence. 25 In this study,
we have fractionated the cell lysate into mitochondria and cytosol and found that p32 was abundantly presented in the mitochondria. Interestingly, downregulation of [p32]m using sip32-targeting mitochondria-targeting sequence ( Figure 3A ) and upregulation of [p32]m in ApoE À/À mice fed an HCD ( Figure 7B ) showed decreased and increased [p32]c, respectively. These results suggest that [p32]c can be released from mitochondrial p32 during mitochondrial events. p32 silencing enhanced mitochondrial fission and the loss of mitochondrial fusion with the loss of detectable levels of Mfn1/2 proteins. 34 Additionally, the difference in molecular weight of p32 observed in Western blot and MALDI-TOF mass spectrometry analysis is probably because of glycosylation and strong charges. 35 In the present study, we report a novel function of p32 in a Ca 2+ -dependent eNOS regulation of ECs. Although how p32
regulates Ca 2+ levels between cytosol and mitochondria remains unknown, we suggest several plausible explanations. uniporter (accession No. NM_138357), however, the siRNA had no effect on [Ca homeostasis is controlled by the endoplasmic reticulum (ER), and mitochondria. First, mitochondrial Ca 2+ uptake can activate several dehydrogenases (pyruvate dehydrogenase, isocitrate dehydrogenase, and a-ketoglutarate dehydrogenase) in the matrix and elevate the respiration rate and ATP production. 37 Consistently, arginase inhibition and sip32 treatment reduced intracellular ATP level ( Figure S9 ). However, a prolonged increase in [Ca 2+ ]m can induce mitochondrial swelling, cytochrome C release, and apoptotic cell death. 38 In addition to altering the mitochondrial activity, increased [Ca 2+ ]c played an important role in eNOS activation through CaM and CaMKII in vascular ECs. CaM binds to a CaM-binding motif that inhibits Thr495 phosphorylation and then facilitates NADPH-dependent electron flow from the reductase domain to the oxygenase domain by displacing an adjacent autoinhibitory loop of eNOS. CaMKII mediates Ser1177 phosphorylation in the reductase domain, and then NO production is increased by enhancing the electron flux through the reductase domain. 39 Therefore, arginase activity adjusts the phosphorylation of 2 important amino acids, Ser1177 and Thr495, when eNOS is activated through a Ca 2+ -dependent mechanism. NO generated by eNOS increases mitochondrial biogenesis and enhances respiration and ATP content. 40 Reciprocally, arginase inhibition increased NO production, and L-Arg supplementation increased [Ca 2+ ]c ( Figure 4A ). Therefore, we investigated the effect of arginase inhibition on [Ca 2+ ]m in eNOS À/À mice to clearly demonstrate arginase inhibition Figure 5 . Arginase II inhibition reduced SPM level, and siArgII and gene knockout decreased p32 protein level. A, Intracellular SPM amounts were measured using HPLC in siRNA (siArgII and scmRNA)-and ABHtreated HUVECs., n=3 independent experiments. B, siArgII (100 nmol/L) were incubated with HUVECs for 24 hours, and p32 level was detected in both mitochondria and cytosol fractions using Western blot analysis. Detection of arginase II was used as a control for siArgII treatment (n=4 independent experiments). C, Aortas of WT and ArgII À/À mice were isolated, and mitochondria and cytosol fractions were separated. P32 and arginase II expression levels were detected (n=4 independent experiments from 4 mice). D, Aortic lysates from WT and ArgII À/À mice were analyzed using HPLC to L-Arg and SPM. ns, nonsignificant, n=4 independent experiments from 4 mice. HPLC indicates high performance liquid chromatography; HUVECs, human umbilical vein endothelial cells; siRNA, small interfering RNA; SPM, spermine; WT, wild-type. *vs WT, P<0.01. Figure S3 , arginase inhibition with ABHinduced CaMKII phosphorylation, and arginase II and mitochondrial p32 expressions were significantly augmented (A and B). Consistent with previous results, [Ca 2+ ]m in ECs from eNOS À/À mice was increased compared with that of WT mice, which was reduced by the arginase inhibitor, ABH, comparable to ECs from ArgII À/À mice (C). Therefore, Ca 2+ /CaMKII/ eNOS axis phosphorylation caused by arginase inhibition was attributed not to increase NO production, but to arginasedependent p32 regulation. Uncoupled eNOS is an important ROS-producing enzyme contributing to atherogenesis in HCD-fed ApoE À/À mice. As shown in Figure S10 , increased ROS production in HCD-fed ApoE À/À mice was attenuated with treatment of NG-nitro-Larginine methyl ester, ABH, sip32, and diphenyleneiodonium (DPI, NADPH oxidase inhibitor). These data indicate that NADPH oxidase and uncoupled eNOS are major sources for ROS production in atherogenesis. Several mechanisms have been implicated in eNOS uncoupling under pathophysiological conditions, including: (1) L-arginine depletion; (2) cofactor depletion; (3) altered eNOS phosphorylation; and (4) HCD. These results underly a novel mechanism for arginasedependent constriction of eNOS activity. In this study, p32 was identified as a new therapeutic target for vascular disorders such as atherosclerosis in which NO production was Figure 6 . sip32-induced NO-dependent vasorelaxation in the aortas of WT mice. A, Aortic segments from WT mice were incubated with siRNA (final concentration,100 nmol/L) for 24 hours. p32 level was detected using Western blot analysis after mitochondrial fractionation (n=4 independent experiments from 4 mice). B, Aortas of WT mice were treated with siRNA, and proteins phosphorylation was analyzed using Western blotting (n=3 independent experiments from 3 mice). NO production (C) and ROS generation (D) were measured as timedependent changes in DAF (4-amino-5-methylamino-2',7'-difluorofluorescein) and DHE (dihydroethidine) fluorescence intensities, respectively. The slopes were defined as the change in fluorescence intensity, and relative slopes are presented as a bar graph. siRNA and ABH (2(S)-amino-6-boronohexanoic acid) were incubated with aortas for 24 hours. NG-nitro-L-arginine methyl ester (100 lmol/L) was used as a control (n=8 aortic segments from 4 mice). Endothelium-dependent vasorelaxation responses to A (E), endothelium-independent relaxation responses to SNP (F), and contractile responses to PE (G) were determined using siRNA-treated aortas (n=8 aortas from 4 mice). NO indicates nitric oxide; ROS, reactive oxygen species; siRNA, small interfering RNA; WT, wild-type. *vs untreated, P<0.01.
effects. As shown in
interrupted and injurious ROS generation was promoted by endothelial dysfunction. ]m, respectively. Fluorescence intensities are presented as a bar graph (n=15 images from 3 mice). E, WT and ApoE À/À mice were fed an ND and HCD and siRNAs were administered by intravenous injection 5 times before the experiment. The p32 protein level was determined after mitochondrial fractionation (n=3 experiments from 3 mice). F, Protein phosphorylation was analyzed using Western blotting (n=4 experiments from 4 mice). NO (G) and ROS (H) production in aortic endothelia was determined using DAF and DHE fluorescence dyes, and the slopes are presented as a bar graph (n=6 experiments from 3 mice). I, Vasodilator dose responses to Ach and SNP (inset) in the aortas of WT+ND and ApoE À/À +HCD injected with siRNAs were determined (n=12 from 3 mice). J, Dose-response effects of PE on vascular constriction were then determined (n=12 from 3 mice). DAF indicates 4-amino-5-methylamino-2 0 ,7 0 -difluorofluorescein; DHE, dihydroethidine; HCD, high cholesterol diet; HPLC, high performance liquid chromatography; ND, normal diet; ROS, reactive oxygen species; siRNA, small interfering RNA; sip32, siRNA against p32; SPM, spermine; WT, wild-type.*vs WT+ND, P<0.01; **vs WT+ND with SPM;
## ApoE À/À +HCD vs ApoE À/À +HCD+sip32, P<0.01. Figure S4 . Arginase inhibition and L-Arg supplement had no effect on p32 protein level, and sip32 was not associated with arginase II expression and activity. The arginase inhibitor ABH (A) and substrate L-Arg (B) were incubated with HUVECs for different time periods, and p32 protein expression was examined using western blot analysis after mitochondrial fractionation. HUVECs treated with sip32 were analyzed for arginase II expression (C) and arginase activity (D). n=3 independent experiments. L-Arg, L-arginine. 
